Like what I heard at UBS conference. Acceleration clause would kick in if Mayne is acquired. I think that would about cover next years Montigen's pipeline costs. Manuso also mentioned several times the past three weeks that big pharma is paying more for the first time for preclinical drugs. This could eliminate any burn if someone takes a serious look at SUPG pipeline. The other point I liked was that clause in Manuso contract about a buyout. I looked at his January 1, 2004 contract and no mention on this subject. Why would they pick a date of Jan. 31, 2007 for such a clause. His contract is for 3 years. He gets options every year...would it not make sense to state a longer period on this clause? We have a solid balance sheet and strong growth in their Dacogen drug. I expect to here something on Orethecin soon. When those ducks fall in place we'll be Larry-free.